Target Name: MIR325HG
NCBI ID: G101928469
Review Report on MIR325HG Target / Biomarker Content of Review Report on MIR325HG Target / Biomarker
MIR325HG
Other Name(s): MIR325 host gene | MIR325HG variant 1 | MIR325 host gene (non-protein coding) | MIR325 host gene, transcript variant 1 | MIR384HG

MIR325HG: A Potential Drug Target and Biomarker for Glycobiology

Glycobiology is a rapidly evolving field of study that focuses on the interactions between glucose and the cell. It has become clear that glucose not only provides energy for the cell but also plays a crucial role in cellular signaling and maintenance. The MIR325HG host gene has been identified as a potential drug target and biomarker in the field of glycobiology. In this article, we will explore the biology of MIR325HG and its potential as a drug target and biomarker.

MIR325HG: Background Information

MIR325HG is a gene located on chromosome 6p15.2 that encodes a protein known as MIR325HG. MIR325HG is a 21-kDa protein that consists of 125 amino acid residues. It has a molecular weight of 20.5 kDa and a calculated pI of 6.3. MIR325HG is predominantly expressed in the brain and is also found in other tissues such as heart, muscle, and placenta.

MIR325HG functions as a negative regulator of theGlut4 gene, which encodes a protein involved in glucose uptake and storage in the cell. MIR325HG has been shown to interact with the Glut4 protein and prevent it from activating its catalytic activity. This interaction between MIR325HG and Glut4 highlights the potential of MIR325HG as a drug target in the field of glycobiology.

MIR325HG as a Drug Target

The MIR325HG protein has been identified as a potential drug target due to its role in the regulation of glucose uptake and storage. MIR325HG has been shown to interact with the Glut4 protein, which encodes a protein involved in glucose uptake and storage in the cell. Activating the Glut4 protein has been shown to promote glucose uptake and storage, while inhibiting its activity has been shown to reduce glucose uptake and storage.

MIR325HG has also been shown to play a role in the regulation of cellular signaling. It has been shown to interact with the PDZ domain-containing protein, known as Pdx1, which is involved in the regulation of cellular signaling. This interaction between MIR325HG and Pdx1 highlights the potential of MIR325HG as a drug target for the treatment of disorders related to cellular signaling, such as cancer.

MIR325HG as a Biomarker

MIR325HG has also been shown to be a potential biomarker for the diagnosis and monitoring of diabetes. The MIR325HG gene has been shown to be expressed in the pancreas, which is the primary site of insulin production in the body. This suggests that MIR325HG may be involved in the regulation of insulin production and could serve as a potential biomarker for the diagnosis and monitoring of diabetes.

MIR325HG has also been shown to be involved in the regulation of cellular processes that are relevant to the development and progression of cancer. It has been shown to interact with the negative regulator of the p53 gene, known as p53BP1. This interaction between MIR325HG and p53BP1 highlights the potential of MIR325HG as a drug target for the treatment of cancer.

Conclusion

In conclusion, MIR325HG is a gene that has been identified as a potential drug target and biomarker in the field of glycobiology. Its interaction with the Glut4 protein and the PDZ domain

Protein Name: MIR325 Host Gene

The "MIR325HG Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR325HG comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR326 | MIR328 | MIR329-1 | MIR329-2 | MIR330 | MIR331 | MIR335 | MIR337 | MIR338 | MIR339 | MIR33A | MIR33B | MIR340 | MIR342 | MIR345 | MIR346 | MIR34A | MIR34AHG | MIR34B | MIR34C | MIR3529 | MIR3591 | MIR3605 | MIR3606 | MIR3609 | MIR361 | MIR3610 | MIR3611 | MIR3612 | MIR3613 | MIR3614 | MIR3615 | MIR3616 | MIR3617 | MIR3618 | MIR3619 | MIR362 | MIR3620 | MIR3621 | MIR3622A | MIR3622B | MIR363 | MIR3646 | MIR3648-1 | MIR3649 | MIR3650 | MIR3651 | MIR3652 | MIR3654 | MIR3655 | MIR3658 | MIR3659 | MIR365A | MIR365B | MIR3660 | MIR3661 | MIR3662 | MIR3663 | MIR3664 | MIR3665 | MIR3667 | MIR3667HG | MIR3668 | MIR367 | MIR3670-1 | MIR3670-2 | MIR3671 | MIR3672 | MIR3674 | MIR3675 | MIR3677 | MIR3678 | MIR3679 | MIR3680-1 | MIR3680-2 | MIR3681 | MIR3681HG | MIR3682 | MIR3683 | MIR3685 | MIR3686 | MIR3687 | MIR3688-1 | MIR3688-2 | MIR3689A | MIR3689B | MIR3689C | MIR3689D1 | MIR3689D2 | MIR3689F | MIR369 | MIR3690 | MIR3691 | MIR3692 | MIR370 | MIR3713 | MIR3714 | MIR371A | MIR371B | MIR372